Clinical trials
Advanced Hepatocellular Carcinoma clinical trials
Below are recruiting advanced hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 248 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05620706Recruiting
GPC-3 CAR-T for advanced liver cancer
This trial tests CAR-T cell therapy (immune cells changed to target GPC-3) for advanced hepatocellular carcinoma, especially when standard treatments no longer work or you cannot tolerate them. If eligible, the goal is to shrink tumors and help you live longer with improved cancer control.
Shenzhen, GuangdongAges 40–70 - NCT05926726Recruiting
GPC3-targeted CAR-T for advanced liver cancer
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
ShanghaiAges 18–75 - NCT05954897RecruitingPhase 2
Lenvatinib plus tislelizumab with HAIC for advanced liver cancer
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
Guangzhou, GuangdongAges 18 years+ - NCT06201065RecruitingPhase 3
Targeted therapy and immunotherapy for advanced liver cancer
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Guangzhou, GuangdongAges 18–75 - NCT07863258Recruiting
AI matchmaking for advanced liver cancer treatment
This study uses artificial intelligence to look at tumor samples and MRI scans from people with advanced liver cancer to help choose the best treatment. It aims to make treatment more personalized and effective.
AnderlechtAges 18 years+ - NCT06326502RecruitingPhase 1
A study of ETN101 for advanced liver cancer
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
SeoulAges 19–65 - NCT06363006RecruitingPhase 1
Cardonizumab plus TKI for advanced liver cancer after prior treatment
This trial tests a combination of an immunotherapy drug (Cardonizumab) and a targeted therapy pill (TKI) for people with advanced liver cancer whose prior treatment has stopped working. The goal is to see if this second-line combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06363825RecruitingPhase 2
New combination therapy for advanced liver cancer
This trial tests a combination of treatments for advanced liver cancer: a targeted therapy (apatinib), an immunotherapy (camrelizumab), and two local treatments (TAE and HAIC). It may be an option if you have a high tumor burden or a tumor thrombus in the portal vein and haven't had systemic treatment before.
FuzhouAges 18–80 - NCT05738616RecruitingPhase 3
Testing lenvatinib plus TACE and immunotherapy before liver surgery
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Chengdu, SichuanAges 18–75 - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT07832006RecruitingPhase 2
Combination treatment for advanced liver cancer
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, ChinaAges 18–75 - NCT06470256RecruitingPhase 1
Surgery plus targeted therapy and immunotherapy for advanced liver cancer
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
Wuhan, HubeiAges 18–75 - NCT06478927Recruiting
Palbociclib for advanced liver cancer after other treatments
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
Zhengzhou, HenanAges 18–75 - NCT07793695RecruitingPhase 2
Zinc plus immune therapy for advanced liver cancer
This study tests whether adding zinc supplements to standard targeted and immunotherapy improves outcomes for people with advanced liver cancer. Zinc may help the immune system work better against cancer cells.
Hefei, AnhuiAges 18–75 - NCT06550921Recruiting
Ablation plus lenvatinib and immunotherapy for advanced liver cancer
This trial tests whether adding a targeted procedure (ablation) to burn away cancer spots, when combined with lenvatinib and an immunotherapy drug (PD-1 inhibitor), can help control liver cancer that has spread to a few places. It's for people whose liver tumors are already responding to treatment.
Beijing, None SelectedAges 18–75 - NCT06624098Recruiting
Early TIPS for Advanced Liver Cancer with Vein Blockage
This study tests whether placing a small tube (TIPS) early in people with advanced liver cancer and a vein blockage helps their other treatments work better. It is for patients who are already taking lenvatinib and immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT07689175RecruitingPhase 2
Testing a flexible dose of immunotherapy for advanced liver cancer
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
Dallas, TexasAges 18 years+ - NCT06595108Recruiting
Targeted therapy and radiation for advanced liver cancer
This trial tests a combination of immunotherapy (atezolizumab), targeted therapy (bevacizumab), and targeted radiation for advanced liver cancer that cannot be surgically removed. The goal is to see if this approach helps control the cancer.
Yongin-siAges 19–80 - NCT06461624RecruitingPhase 1
GPC3 CAR-T cell therapy for advanced liver cancer
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Hangzhou, ZhejiangAges 18–70 - NCT05072041Recruiting
Degradable chemo bead treatment for liver cancer
This trial studies a new type of “degradable” chemo bead delivered through a catheter to treat hepatocellular carcinoma (HCC). It aims to check safety and whether the treatment works when surgery or transplant is not an option.
Seoul, SeoulAges 19–79 - NCT06301399RecruitingPhase 2
Rituximab with prior therapy for advanced liver cancer
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 17–79 - NCT06694636Recruiting
RF Ablation of Nerve for Advanced Liver Cancer
This trial tests whether using radiofrequency ablation (using heat energy) to target specific nerves can help treat advanced liver cancer (HCC) that has spread or grown despite standard treatments.
Nanjing, JiangsuAges 25–75 - NCT07607769Recruiting
Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
AnconaAges 18–100 - NCT06609863Recruiting
Triple therapy for large liver cancer tumors
This trial tests combining a special type of chemo delivered directly to the liver (dTACE-HAIC) with two immunotherapy drugs (bevacizumab and atezolizumab) for people with huge liver cancer tumors (10 cm or larger). The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, None SelectedAges 18–75
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Advanced Hepatocellular Carcinoma trials by city
Studies with a site in or near these metro areas.
Advanced Hepatocellular Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for advanced hepatocellular carcinoma?
- Yes. Clin2 currently lists 248 recruiting advanced hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.